XERIS BIOPHARMA HOLDINGS, INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-12-31 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-09-30 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2025 was $15.15M.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2024 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2023 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2020 was $39.94M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $11.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $15.15M 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $15.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $11.96M 10-Q · filed 2026-08-06 | $15.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.19M 10-Q · filed 2026-08-06 | $3.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $0.00 10-K · filed 2026-03-02 | |
| 2022-03-31 | $2.08M 10-Q · filed 2022-08-10 | |
| 2020-12-31 | $38.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $39.94M 10-K · filed 2022-03-11 |
| 2020-09-30 | $1.06M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |